TIM
AMED

Tevis Investment Management’s Amedisys AMED Stock Holding History

Tevis Investment Management’s Portfolio AMED Stock Details AMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-38
Closed -$7K – 479
2022
Q1 		$7K Hold
38
– – 0.01% 411
2021
Q4 		$6K Buy
+38
New +$6.11K 0.01% 477

Other funds holding AMED

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RP
Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Tevis Investment Management's AMED Position: Q2 2022 in Review

Tevis Investment Management sold out of Amedisys (AMED) in Q2 2022, closing a stake of 38 shares — an estimated $7K sold.

Tevis Investment Management first reported a position in AMED in Q4 2021 and held it in 2 quarters. The position peaked at $7K in Q1 2022. 288 funds tracked by Wall St. Rank hold AMED as of Q2 2022.

  • Tevis Investment Management reported no remaining Amedisys position as of Q2 2022 after selling out during the quarter.
  • Tevis Investment Management sold 38 Amedisys shares in Q2 2022, an estimated $7K.
  • Tevis Investment Management first reported a position in Amedisys in Q4 2021 and held it in 2 quarters.
  • Tevis Investment Management's Amedisys position peaked at $7K in Q1 2022.
  • 288 funds tracked by Wall St. Rank held Amedisys as of Q2 2022.

Based on Tevis Investment Management's 13F filing for Q2 2022, filed 8 Aug 2022.